Opendata, web and dolomites

PersonalizeAF SIGNED

Personalized Therapies for Atrial Fibrillation. A Translational Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PersonalizeAF project word cloud

Explore the words cloud of the PersonalizeAF project. It provides you a very rough idea of what is the project "PersonalizeAF" about.

academic    individual    partnership    silico    point    13       patient    substrates    exceeding    staff    disease    stakeholders    characterization    multinational    evaluation    sectorial    generation    health    budget    specialised    care    strategies    technologies    medical    view    train    effect    human    cardiac    treatments    purpose    data    careers    equivalent    young    companies    treatment    individualized    career    cardiology    million    disseminate    billion    combining    efficient    outstanding    europeans    annually    vocational    substrate    fibrillation    scientific    services    af    delivering    create    models    muscle    public    aggregates    biomedical    personalizeaf    encourage    training    engineering    mechanisms    arrhythmia    personalised    innovative    spectrum    efficiency    world    guarantee    generate    clinical    students    atrial    sectors    therapy    skilled    vitro    profile    individually    integrate    animal    progress    commensurate    date    multidisciplinary    professionals    phd    description    ex    therapies    search    esrs    vivo   

Project "PersonalizeAF" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT POLITECNICA DE VALENCIA 

Organization address
address: CAMINO DE VERA SN EDIFICIO 3A
city: VALENCIA
postcode: 46022
website: www.upv.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙943˙449 €
 EC max contribution 3˙943˙449 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT POLITECNICA DE VALENCIA ES (VALENCIA) coordinator 501˙809.00
2    KARLSRUHER INSTITUT FUER TECHNOLOGIE DE (KARLSRUHE) participant 758˙365.00
3    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 531˙239.00
4    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 303˙172.00
5    SIMULA RESEARCH LABORATORY AS NO (FORNEBU) participant 292˙342.00
6    UNIVERSITE DE BORDEAUX FR (BORDEAUX) participant 274˙802.00
7    NCARDIA BV NL (LEIDEN) participant 265˙619.00
8    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 261˙499.00
9    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 252˙788.00
10    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 250˙904.00
11    FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANON ES (MADRID) participant 250˙904.00

Map

 Project objective

Atrial Fibrillation (AF) is the most common cardiac arrhythmia affecting more than 6 million Europeans with a cost exceeding 1% of the EU health care system budget (13.5 billion annually). New treatment strategies and the progress achieved in research on AF mechanisms and substrate evaluation methods to date have not been commensurate with an equivalent development of the knowledge and technologies required to individually characterize each patient in search of the most efficient therapy.

PersonalizeAF addresses this challenge by delivering an innovative multinational, multi-sectorial, and multidisciplinary research and training programme in new technologies and novel strategies for individualized characterization of AF substrate to and increase treatments’ efficiency.

From the research point of view, PersonalizeAF will integrate data and knowledge from in-vitro, in silico, ex vivo and in vivo animal and human models to: 1) generate an individual description of the state of the atrial muscle identifying the disease mechanisms and characteristics; 2) understanding the potential effect that different therapies have on different atrial substrates; and 3) combining this information to generate a specific profile of the patient and the best therapy for each patient.

With this purpose, PersonalizeAF partnership aggregates relevant scientific staff from the academic and clinical world with highly specialised biomedical companies which will be involved in a high-level personalised training programme that will train a new generation of highly skilled professionals and guarantee ESRs and future PhD students outstanding Career Opportunities in the biomedical engineering, cardiology services and medical devices sectors. PersonalizeAF will disseminate results to a wide spectrum of stakeholders, create awareness in the general public about atrial fibrillation and encourage vocational careers among young students.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERSONALIZEAF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERSONALIZEAF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

HeatNMof (2020)

Heating triggered drug release from nanometric inorganic-metal organic framework composites

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More